The recent Ebola virus outbreak in central Africa is a growing concern for global health organizations. As the Bundibugyo ebolavirus affects individuals in Uganda and the Democratic Republic of the Congo, both the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) issued statements urging international caution. The CDC announced it had implemented enhanced travel screening, entry restrictions, and public health measures, while the WHO labeled the situation as a "public health emergency of international concern."

The Bundibugyo ebolavirus, an uncommon species of Ebolavirus, has no approved vaccines or specific treatments. In total, there are six species of Ebolavirus: Bombali ebolavirus, Bundibugyo ebolavirus, Reston ebolavirus, Sudan ebolavirus, Tai Forest ebolavirus, and Zaire ebolavirus.

Today, we’re showcasing some of the latest Ebola-related articles published recently across medical journals, followed by insights from the CDC and a look at U.S. Food and Drug Administration (FDA)-approved therapeutics for the Zaire ebolavirus, the only Ebolavirus species with approved therapies. Some article descriptions were edited for clarity and brevity.

Ebola: WHO Declares Emergency as Strain with no Vaccine Kills 100 in DRC and Uganda

  • BMJ
  • May 2026
  • Description: A new outbreak of Ebola virus disease in central Africa, caused by the rare Bundibugyo version of the virus, has caused more than 300 suspected cases and killed 100 people, health officials have said. The World Health Organization (WHO) has declared the situation a public health emergency of international concern.
  • Summary
  • Full Text

Investigation of the Epidemiological Transition of Ebola Virus Under Contagious Population with Sustainable Extended Fractional Operator

  • Mathematical Biosciences
  • May 2026
  • Description: The Ebola outbreak represents one of the most severe global health crises in recent history. In this study, we develop and analyze a new fractional-order mathematical model for the transmission dynamics of the Ebola virus, incorporating an extended Atangana-Baleanu Caputo fractional operator. The model’s foundational properties-such as existence, uniqueness, positivity, and well-posedness of solutions are established through fixed point theorems. A detailed investigation of the basic reproduction number is carried out, accompanied by a sensitivity analysis to highlight influential parameters affecting disease spread.
  • Summary
  • Full Text

Exploring Ebola Virus-Associated Gene Expression Through Comparative Analysis

  • Frontiers in Genetics
  • April 2026
  • Description: Ebola virus (EBOV) infection triggers intense host transcriptional responses that overlap extensively with those induced by other viral and bacterial pathogens. This overlap complicates the identification of EBOV-specific gene expression signatures and limits diagnostic specificity. Defining transcriptional markers that distinguish EBOV from other infections is essential for improving molecular diagnostics and advancing understanding of EBOV-specific host responses.
  • Summary
  • Full Text

QSAR-Guided and Fragment-Based Drug Design of Monoterpenoid Inhibitors Targeting Ebola Virus Glycoprotein

  • International Journal of Molecular Sciences
  • March 2026
  • Description: Ebola virus disease remains one of the most serious viral infections with no approved small-molecule treatments. The Ebola virus glycoprotein (EBOV-GP), which enables the virus's entry to host cells, is a promising target for drug discovery. In this study, a multistage computer-aided drug discovery approach was used to identify new specific EBOV-GP inhibitors. A reliable QSAR model was built using 55 terpenoid derivatives. This model was able to predict the activity of newly designed compounds with good accuracy and validated statistical metrics [...] This study showed how combining QSAR, fragment-based design, docking, ADMET, and molecular dynamics could help in identifying potent and safe small molecules against the EBOV-GP.
  • Summary
  • Full Text
Ebola Disease Insights from the CDC

The CDC provides Ebola disease clinical guidance for U.S-based healthcare providers that covers topics like appropriate screening, evaluation, prevention, and treatment options. The CDC cautions that travelers returning from areas with active Ebola disease outbreaks who are feeling ill will likely have a more common infection rather than Ebola. Quickly identifying the correct pathogens is key to avoiding the delay of identifying true Ebola cases. The CDC states, “[The] consideration of Ebola disease should not delay diagnostic assessments, laboratory testing, and appropriate care for other, more likely medical conditions [..] It is important to systematically assess patients through a screening process and treat infections as they are discovered.”

Additionally, the CDC has separate clinical guidance for U.S.-based healthcare providers that focuses on Ebola virus and pregnant women. While it states that there is no current evidence that pregnant women are more susceptible to infection from Ebolavirus than the general population, it cautions that pregnant women are at increased risk of severe illness and death when infected by the virus during pregnancy. 

FDA-Approved Therapies and Vaccine

The U.S. Food and Drug Administration approved two medications for treating infection caused by Ebolavirus: Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), and Ebanga (Ansuvimab-zykl). Inmazeb was approved in October 2020, Ebanga was approved two months later in December 2020. Both medications are indicated for the treatment of infection caused by Zaire ebolavirus.

Both Inmazeb and Ebanga are approved for adults and pediatric patients, including neonates whose mothers tested positive for the infection. 

In 2019, the FDA approved Ervebo, the first vaccine for an ebolavirus, specifically the Zaire ebolavirus.

Don’t miss our other rundown articles and sign up for alerts and stay informed on the latest published articles and guidelines.